Lab Reference Library / Prolactin Hormones & Reproductive

Prolactin

Prolactin · PRL · Lactogenic Hormone

Reference range, optimal functional medicine levels, and why elevated prolactin suppresses testosterone, estrogen, and gonadotropin release through hypothalamic GnRH inhibition, how to distinguish medication-induced from tumor-driven hyperprolactinemia, and when pituitary MRI is clinically indicated.

Pituitary HormoneGonadotropin Regulator

Women FM OptimalBelow 15 ng/mL

Men FM OptimalBelow 10 ng/mL

Adenoma ConcernAbove 100 ng/mL

Unitsng/mL

← Back to Lab Reference Library

Category: Hormones & Reproductive | Also known as: PRL, Lactogenic Hormone, Mammotropin, Luteotropic Hormone

1. What This Test Measures

Prolactin (PRL) is a 23-kilodalton polypeptide hormone produced primarily by lactotroph cells in the anterior pituitary gland, with smaller amounts produced by decidual cells in the uterus, lymphocytes, breast tissue, and the brain. Unlike most pituitary hormones, prolactin secretion is predominantly under tonic inhibitory control rather than stimulatory control: hypothalamic dopamine neurons project to the pituitary portal circulation and continuously suppress prolactin release through D2 receptor signaling on lactotrophs. Prolactin rises when dopamine signaling is interrupted, whether by pharmacological D2 blockade, hypothalamic mass lesion, or pituitary stalk compression. Conversely, stimuli that raise prolactin include: suckling (through nipple mechanoreceptors triggering spinal cord reflexes that suppress hypothalamic dopamine), sleep (prolactin peaks during deep slow-wave sleep and is one of several hormones showing nocturnal surges), stress (including psychological stress and physical exertion), thyrotropin-releasing hormone (TRH, which is why hypothyroidism elevates prolactin), and estrogen (which stimulates lactotroph proliferation and prolactin gene expression).

The primary physiological role of prolactin is to initiate and maintain lactation in postpartum women through its stimulatory effect on mammary gland alveolar cells; prolactin also promotes the growth and differentiation of mammary ductal cells during pregnancy in concert with estrogen and progesterone. Beyond lactation, prolactin has immunomodulatory effects on lymphocyte function, roles in glucose metabolism, a potential neuroprotective function in the brain, and effects on adipose tissue metabolism. The most clinically important non-lactational role of prolactin is its potent suppressive effect on the hypothalamic-pituitary-gonadal (HPG) axis: prolactin inhibits GnRH pulsatility from the hypothalamus, reducing LH and FSH release from the pituitary, and thereby suppressing gonadal sex hormone production. This is the physiological basis for lactational amenorrhea (why breastfeeding suppresses ovulation) and the mechanism through which pathological hyperprolactinemia causes infertility, hypogonadism, and sexual dysfunction in both sexes.

In functional medicine practice, prolactin is measured in the evaluation of infertility, menstrual irregularity, unexplained low libido, erectile dysfunction, secondary hypogonadism (low testosterone with low LH), gynecomastia in men, galactorrhea, and suspected pituitary pathology. It is an essential measurement whenever the pattern of low gonadotropins (LH and FSH) with low sex hormones suggests central rather than primary hypogonadism, because hyperprolactinemia is the most common pituitary tumor-related cause of this pattern and is highly treatable.

2. Reference Range and Optimal Levels

Population	Standard Reference	FM Optimal	Interpretation
Women (non-pregnant, non-lactating)	2.0 to 29.0 ng/mL	Below 15 ng/mL	Above 25 warrants repeat fasting testing; above 50 suggests significant cause
Women (pregnant, third trimester)	95.0 to 473.0 ng/mL	Physiological; no action threshold	Dramatic physiological rise; do not interpret outside pregnancy context
Women (lactating)	Variable; can exceed 200 ng/mL	Physiological; suppress when weaning desired	Maintains lactational amenorrhea; falls with reduced nursing frequency
Men (adult)	2.0 to 18.0 ng/mL	Below 10 ng/mL	Above 18 warrants evaluation; above 30 requires medication review and repeat testing
Prolactinoma (microadenoma)	Typically 25 to 200 ng/mL	Not applicable	Requires MRI pituitary; dopamine agonist therapy indicated
Prolactinoma (macroadenoma)	Often above 200 ng/mL	Not applicable	Urgent MRI; risk of visual field defects from optic chiasm compression

Prolactin has significant pulsatile and diurnal variation. Levels are highest during sleep and peak approximately 1 hour after sleep onset. Stress of venipuncture transiently elevates prolactin in some patients. For accurate basal prolactin measurement, the patient should be fasting (no food for 4 hours), non-stressed (seated at rest for 20 to 30 minutes before draw), and the specimen should be drawn in the late morning (not at or shortly after waking). A single elevated result should be confirmed with a repeat fasting measurement before proceeding to imaging or treatment.

3. Causes of Elevated Prolactin: A Systematic Approach

The most important clinical skill in evaluating elevated prolactin is applying a systematic exclusion hierarchy before attributing elevation to a pituitary tumor: physiological causes first, pharmacological causes second, other pathological causes third, and pituitary adenoma last.

Physiological hyperprolactinemia includes pregnancy (always check a beta-hCG before any other evaluation), lactation, nipple stimulation in the 24 hours before the draw, recent sexual intercourse, strenuous exercise in the 2 hours before drawing, and psychological stress. These causes should be excluded by history before attributing any prolactin elevation to pathology. Pharmacological hyperprolactinemia is the most common cause of non-physiological prolactin elevation in clinical practice: dopamine D2 receptor antagonists (haloperidol, risperidone, metoclopramide, domperidone) produce the most dramatic prolactin elevation, sometimes to levels above 100 ng/mL that mimic macroprolactinoma; most antidepressants (particularly SSRIs, but also tricyclics and venlafaxine) elevate prolactin by 2 to 20 ng/mL; opioids suppress dopamine and raise prolactin; verapamil, methyldopa, and ranitidine have documented prolactin-elevating effects. A full medication review, including non-prescription supplements and cannabis (which can transiently elevate prolactin), is mandatory before imaging.

4. Prolactinomas: Diagnosis and Treatment

Microprolactinoma (Adenoma Below 10mm)

Prolactin levels: typically 25 to 200 ng/mL; very high prolactin (above 250 ng/mL) with a small lesion on MRI suggests either macroprolactinemia artifact or a macroadenoma being underestimated on imaging
Clinical presentation: amenorrhea or oligomenorrhea, galactorrhea, infertility, low libido in women; low libido, erectile dysfunction, infertility, gynecomastia in men; often incidentally detected on MRI ordered for other reasons
Treatment with cabergoline: cabergoline (a long-acting D2 agonist) at 0.5mg twice weekly is the first-line treatment for symptomatic prolactinomas; normalizes prolactin in approximately 90% of microprolactinomas; reduces tumor size in most cases; very well-tolerated with substantially lower nausea and psychiatric side effects than bromocriptine; may be discontinued after 2 years if prolactin has normalized and no tumor is visible on MRI; prolactin monitoring every 3 to 6 months during treatment confirms response
Fertility restoration: normalization of prolactin with cabergoline typically restores normal LH and FSH pulsatility within weeks, resulting in return of ovulation and menstrual function in most women within 1 to 3 months; prolactin normalization in men restores testosterone production within 3 to 6 months

Macroprolactinoma (Adenoma 10mm or Larger)

Prolactin levels: typically above 200 ng/mL; often above 500 to 1,000 ng/mL with large lesions; very rarely, large non-secreting adenomas compress the pituitary stalk and elevate prolactin to below 100 ng/mL through stalk effect (distinguished from prolactinoma by the modest prolactin elevation relative to tumor size)
Visual field assessment urgency: macroprolactinomas that extend above the sella turcica can compress the optic chiasm; formal Humphrey visual field testing is required in all patients with macroprolactinoma; bitemporal hemianopia (loss of peripheral vision in both eyes) is the classic pattern from optic chiasm compression
Cabergoline efficacy: cabergoline produces significant tumor shrinkage in approximately 70 to 80% of macroprolactinomas within 3 to 6 months; tumor volume reduction of 50% or more at 6 to 12 months is a favorable response; visual field improvement typically follows tumor shrinkage within weeks of initiation
Surgery and radiation: transsphenoidal neurosurgery is reserved for cabergoline-resistant macroprolactinomas, patients who cannot tolerate dopamine agonists, and cases of acute visual loss from tumor hemorrhage (apoplexy); stereotactic radiosurgery (Gamma Knife) is used for residual tumor after surgery; all surgical and radiation decisions require specialist pituitary neurosurgery and endocrinology collaboration
Long-term monitoring: annual MRI for macroprolactinoma patients during treatment and for 2 years after any medication discontinuation; prolactin measurement every 3 to 6 months on treatment; bone density monitoring (macroprolactinoma-related estrogen or testosterone deficiency impairs bone mineralization)

5. Prolactin and Functional Medicine: The Underdiagnosed Pattern

Medication-induced hyperprolactinemia in functional medicine practice: patients on antidepressants (particularly SSRIs like sertraline, fluoxetine, and paroxetine) commonly have prolactin elevations of 20 to 50 ng/mL that are not routinely checked; when low libido, sexual dysfunction, or menstrual changes develop on antidepressant therapy, prolactin elevation from the medication may be the overlooked cause rather than a depressive symptom; switching to bupropion (a dopamine reuptake inhibitor that does not elevate prolactin) resolves the prolactin-mediated side effects while maintaining antidepressant efficacy in many patients
Opioid-induced hyperprolactinemia: chronic opioid use suppresses hypothalamic dopamine neurons and elevates prolactin; this combined with opioid-induced suppression of GnRH creates a compound hypogonadism in chronic opioid users; checking prolactin in chronic pain patients on opioids who report sexual dysfunction, infertility, or fatigue identifies this reversible cause of gonadal axis suppression
Subclinical hyperprolactinemia and reduced libido: prolactin in the high-normal range (15 to 25 ng/mL in women, 12 to 18 ng/mL in men) may exert meaningful GnRH-suppressive effects on libido and gonadal function in sensitive individuals even without frank hypogonadism; addressing the elevated prolactin through dopamine support (mucuna pruriens, vitamin B6) or medication review may improve libido and sexual function without full-dose dopamine agonist therapy
Vitamin B6 and dopamine support: pyridoxal-5-phosphate (the active form of vitamin B6) is required for L-DOPA decarboxylase activity and dopamine synthesis; B6 deficiency can impair dopamine production and contribute to mildly elevated prolactin through reduced hypothalamic dopamine tone; B6 supplementation at 50 to 100mg daily has documented modest prolactin-lowering effects in women with hyperprolactinemia; use P5P (pyridoxal-5-phosphate) rather than pyridoxine for bioavailability

6. How to Support Healthy Prolactin Levels

Dopamine Support for Mildly Elevated Prolactin

Mucuna pruriens (standardized L-DOPA, 200 to 400mg daily): velvet bean extract containing natural L-DOPA, the direct precursor to dopamine; crosses the blood-brain barrier and supports hypothalamic dopamine production; clinical evidence for prolactin reduction and testosterone improvement in men with hyperprolactinemia; appropriate for mild prolactin elevation in the absence of confirmed adenoma
Vitamin B6 as P5P (50 to 100mg daily): the most clinically evidence-backed nutritional intervention for mild hyperprolactinemia; P5P is required for dopamine synthesis from L-DOPA; several small RCTs demonstrate prolactin reduction with B6 supplementation; use P5P rather than pyridoxine for better bioavailability and less peripheral neuropathy risk at higher doses
Optimize thyroid function: TRH stimulates prolactin release; hypothyroidism with elevated TRH drives prolactin elevation; correcting hypothyroidism, including optimizing Free T3 to the functional optimal range, reduces TRH-driven prolactin secretion; always check TSH and Free T3 in patients with elevated prolactin before pursuing other evaluations
Reduce stress and chronic cortisol burden: psychological stress transiently elevates prolactin through hypothalamic circuits; chronic stress that sustains cortisol elevation impairs dopamine neurotransmitter balance; stress management through parasympathetic activation reduces stress-related prolactin fluctuations

Pharmaceutical Management

Cabergoline (0.25 to 0.5mg once or twice weekly): first-line treatment for confirmed prolactinoma or symptomatic hyperprolactinemia requiring pharmaceutical intervention; monitor prolactin at 4 to 6 weeks after initiation to confirm response; target prolactin below 15 ng/mL in women and below 10 ng/mL in men; check cardiac valvular function (echocardiogram) before starting if cumulative dose will be high, as high-dose long-term cabergoline (primarily used in Parkinson's disease at much higher doses) has been associated with valvular fibrosis
Bromocriptine (2.5 to 7.5mg daily): older, shorter-acting D2 agonist; second-line after cabergoline due to higher nausea, hypotension, and psychiatric side effect frequency; preferred in pregnancy (longest safety data) when prolactinoma treatment is required during gestation
Medication review and substitution: when prolactin elevation is drug-induced, the best intervention is identifying and substituting the offending medication where clinically feasible; bupropion is the preferred antidepressant alternative for patients with prolactin elevation from SSRI therapy; aripiprazole (a partial D2 agonist) produces less prolactin elevation than other antipsychotics and may be a substitution option when antipsychotic therapy is required

Sleep and Lifestyle

Sleep optimization: prolactin is secreted in a sleep-dependent pattern with peak release during slow-wave sleep; paradoxically, total sleep deprivation dramatically lowers prolactin while REM-specific deprivation has less effect; maintaining regular sleep-wake timing and adequate total sleep duration supports normal prolactin diurnal rhythm rather than producing pathological chronic elevation
Reduce cannabis use: cannabis acutely elevates prolactin through cannabinoid receptor-mediated pathways; chronic heavy cannabis use may chronically elevate prolactin and contribute to low testosterone through gonadotropin suppression; reduction or cessation often produces measurable improvement in gonadotropin and testosterone levels within 4 to 6 weeks
Moderate exercise timing: prolactin rises acutely with strenuous exercise (a phenomenon that can confound prolactin measurement if blood is drawn within 2 hours of exercise); regular moderate aerobic exercise at 150 minutes weekly supports hypothalamic-pituitary function; avoid blood draws within 2 hours of any vigorous physical activity for accurate basal prolactin measurement
Address hypoglycemia: reactive hypoglycemia and prolonged fasting trigger stress hormone responses including prolactin elevation; consistent meal timing with adequate protein and fat to prevent glucose crashes reduces stress-mediated prolactin fluctuations; ketogenic and very low carbohydrate diets in some individuals produce reactive hypoglycemia at glucose nadirs that may contribute to prolactin variability

7. Related Lab Tests

LHSuppressed by Elevated Prolactin; LH:FSH Pattern Identifies Central Hypogonadism

→

FSHCo-suppressed With LH by Hyperprolactinemia; Essential Companion Measurement

→

TestosteroneReduced by Prolactin-Mediated LH Suppression in Both Men and Women

→

Free T3Hypothyroidism Elevates TRH Which Stimulates Prolactin; Always Rule Out

→

EstradiolEstrogen Stimulates Lactotroph Proliferation; Elevated Estradiol Raises Prolactin

→

IGF-1Pituitary Function Companion; Concurrent Low IGF-1 Suggests Broader Pituitary Pathology

→

8. Clinical Perspective

Clinical Perspective

Prolactin is the laboratory value that most consistently reveals an overlooked mechanism in patients presenting with what appears to be straightforward low testosterone or sexual dysfunction. When a man comes in with a total testosterone of 220 ng/dL and an LH of 1.4 mIU/mL and a prolactin of 47 ng/mL, that is not a case for immediate TRT; that is a case for pituitary imaging, because a prolactinoma suppressing his LH and therefore his testosterone will respond to cabergoline, will normalize his prolactin, will allow his LH to recover, and will restore his own testosterone production without lifelong exogenous testosterone. Treating it with TRT instead would suppress his residual LH, remove any natural testosterone production he has left, and miss a potentially growing pituitary tumor. Prolactin should be on every male hormone panel. In women, elevated prolactin is the most underappreciated and most treatable cause of menstrual irregularity and infertility presenting to a functional medicine practice, and the treatment with cabergoline is often dramatically effective within one or two monthly cycles. The clinical lesson I keep coming back to is that measuring prolactin costs essentially nothing, adds enormous diagnostic clarity, and in a meaningful percentage of patients with apparent primary hypogonadism or unexplained infertility, reveals a completely different and highly treatable mechanism than what was originally suspected.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

9. Frequently Asked Questions

What symptoms does elevated prolactin cause?

Elevated prolactin produces a characteristic symptom cluster that differs somewhat between men and women. In women: galactorrhea (inappropriate milk production outside of breastfeeding, present in approximately 30 to 80% of hyperprolactinemia cases), menstrual irregularity or amenorrhea (from prolactin-mediated suppression of hypothalamic GnRH and pituitary gonadotropin secretion), infertility, loss of libido, vaginal dryness from the resulting estrogen deficiency, and headaches or visual field defects if a prolactin-secreting pituitary adenoma is large enough to compress the optic chiasm. In men: reduced libido (the most common symptom), erectile dysfunction, gynecomastia (breast tissue enlargement), galactorrhea (less common than in women), infertility from impaired spermatogenesis, and testosterone deficiency from LH suppression.

What causes elevated prolactin other than a pituitary tumor?

The differential diagnosis for elevated prolactin is broad. Physiological causes: pregnancy and lactation produce dramatic prolactin elevation (normal during these states); nipple stimulation briefly elevates prolactin; stress and physical exercise transiently raise prolactin. Pharmacological causes (the most common clinical cause after adenomas): antipsychotic medications (dopamine D2 antagonists like haloperidol, risperidone, and metoclopramide are the most potent prolactin elevators), many antidepressants, opioids, certain antihypertensives (verapamil, methyldopa), and ranitidine. Other pathological causes: primary hypothyroidism (elevated TRH stimulates prolactin; TSH should be checked in all patients with hyperprolactinemia), chronic kidney disease (reduced prolactin clearance), liver cirrhosis, chest wall injury or surgery (triggers the suckling reflex pathway), and rarely ectopic prolactin production from non-pituitary tumors.

How does hyperprolactinemia suppress testosterone in men?

Prolactin suppresses testosterone through multiple simultaneous mechanisms. First, prolactin inhibits hypothalamic GnRH pulsatility through direct receptor signaling on GnRH neurons, reducing LH and FSH release from the pituitary. Reduced LH means less Leydig cell stimulation and less testosterone production. Second, prolactin impairs testicular Leydig cell steroidogenesis directly through prolactin receptor signaling that reduces the expression of steroidogenic enzymes. Third, in long-standing hyperprolactinemia, the LH suppression produces secondary testicular atrophy that further reduces testosterone production capacity. The result is a secondary hypogonadism pattern (low testosterone, low LH, low FSH) from a pituitary-level cause rather than a testicular problem, making it important to measure prolactin in all men presenting with this pattern before attributing it to primary pituitary or hypothalamic hypogonadism.

When should MRI of the pituitary be ordered for elevated prolactin?

MRI of the pituitary with gadolinium contrast should be ordered when serum prolactin is confirmed elevated on two separate measurements drawn in a fasting, non-stressed state and after excluding drug causes and hypothyroidism. The threshold at which MRI is most urgent varies: prolactin above 100 ng/mL almost always indicates a prolactinoma (lactotroph adenoma); prolactin above 200 ng/mL strongly suggests a macroprolactinoma (greater than 10mm); prolactin above 500 ng/mL is virtually diagnostic of macroprolactinoma. Prolactin between 25 and 100 ng/mL has a broader differential and requires careful exclusion of drug causes and hypothyroidism before imaging, as medications are the most common cause of mild to moderate prolactin elevation. A normal pituitary MRI with persistently elevated prolactin suggests medication effect, macroprolactinemia (immunologically active but biologically inactive large prolactin aggregates), or idiopathic hyperprolactinemia.

What is macroprolactinemia and why does it matter?

Macroprolactinemia refers to the presence of high-molecular-weight prolactin aggregates (primarily prolactin-IgG immune complexes, called macroprolactin or big-big prolactin) in the serum. These aggregates are immunologically detected by standard prolactin immunoassays and elevate the measured prolactin level, but they have very low receptor binding activity and are biologically inactive. Patients with macroprolactinemia have elevated serum prolactin without any of the symptoms of true hyperprolactinemia and do not require treatment or pituitary MRI. Macroprolactinemia is identified by the polyethylene glycol (PEG) precipitation test, which removes IgG-bound prolactin from serum; recovery of less than 40% of prolactin after PEG precipitation confirms macroprolactinemia. This test should be ordered before pursuing MRI in asymptomatic patients with unexpectedly elevated prolactin.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

Prolactin is the most commonly missed pituitary hormone in male hypogonadism and unexplained female infertility. It should be on every comprehensive hormone panel before TRT or fertility treatment begins.

Prolactin is a standard component of The Lamkin Clinic comprehensive hormone panel. Schedule a consultation for a complete pituitary-gonadal axis evaluation and personalized hormone optimization plan.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.